Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Seres Therapeutics, Inc.

MCRB ✗ NOT COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$5.01

▼ -1.76%

Market Cap $49.81M · Vol 12.92K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$49.81M

Micro Cap

Div Yield

N/A

EPS Growth

-649.22%

YoY

RSI (14)

58.18

Momentum

Beta

0.26

vs Market

52W High

$29.66

83.11% below

52W Low

$4.33

15.84% above

Volume

12.92K

Avg 16.52K

P/B

3.22

Price-to-book

ROE

N/A

Return on equity

Free Float

88.51%

Public shares

Shariah Compliance8 STANDARDS

✗ Seres Therapeutics, Inc. (MCRB) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MCRB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-11.17%

+7.97%

-20.73%

-43.90%

YTD

-66.33%

-71.49%

-91.76%

-96.00%

Financials & Valuation

TTM · Annual

Total Revenue	$789.00K
Net Income	$5.70M
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-11,779.97%
Net Profit Margin	721.93%
ROE	N/A
ROA · ROIC	4.10% · 19.64%

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	0.22
P/S	167.28
P/B	3.22
P/FCF	152.58
EPS Growth	-649.22%
Outstanding Shares	9.94M

Technical Indicators

50-Day SMA	$5.27
200-Day SMA	$9.40
RSI (14)	58.18
Beta	0.26
52-Week High	$29.66
52-Week Low	$4.33

Volume Today	12.92K
Avg Daily Volume (30D)	16.52K
Relative Volume	0.78x
Volatility (10D)	62.22
Volatility (30D)	64.20
Free Float	88.51%

Analyst Consensus

BUY

Current Price $5.01

Mean Target $17.00

52W Low$4.33 52W High$29.66

Current

Target

$4.33 $29.66

Current Analyst target

+239.32% upside potential · 2 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG0099X6868

ISINUS81750R2013

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -1.15% ARGX.BR argenx SE -0.23% ARGX argenx SE +0.04% INSM Insmed Incorporated +1.67% 2269.HK WuXi Biologics (Cayman) Inc. -1.05%

Company Profile

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.